Why are these stocks considered cheap?

These stocks trade at low valuations relative to their sector peers, suggesting a potential investment opportunity before the market recognizes their true value.

Is healthcare better than tech in 2026?

According to the report, healthcare is quietly outperforming mega-cap tech in 2026, but it doesn't necessarily mean it's better; it may offer different investment opportunities.

What are the risks associated with these stocks?

Risks include regulatory challenges, changes in healthcare policies, and market competition. Low valuations may reflect these risks.

Should I buy these stocks now?

This article does not provide a buy recommendation. It is advisable to conduct independent research or consult a financial advisor before making an investment decision.

2 Absurdly Cheap Healthcare Stocks to Buy Before July Ends

Healthcare is quietly outperforming tech in 2026, and two S&P 500 giants trade at valuations that suggest the market hasn't caught on yet.

July 22, 2026

2 min read

Source: 24/7 Wall St.

According to a report from 24/7 Wall St., healthcare is quietly stealing the spotlight from mega cap tech in 2026, and two S&P 500 giants are trading at valuations that suggest the market has not caught on yet.

Details

The report did not explicitly name the two stocks, but it highlighted that the healthcare sector is experiencing steady growth, and some large-cap companies remain undervalued. Potential candidates include Pfizer (PFE) and CVS Health (CVS), both part of the S&P 500.

Context

In 2026, mega-cap tech stocks like NVIDIA (NVDA) have dominated investor attention, but healthcare has begun to attract interest due to its stability and consistent growth. The low valuations of some healthcare stocks could present an attractive buying opportunity.

What This Means for Investors

Investors should consider the strong fundamentals of major healthcare companies, especially those trading at low price-to-earnings ratios relative to the sector average. However, caution is warranted, as low valuations may be justified by regulatory or operational risks.

Frequently Asked Questions

The report did not name specific stocks, but likely candidates include Pfizer (PFE) and CVS Health (CVS) as undervalued S&P 500 giants.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.